Abstract
The expression of monoclonal antibody (Moab)-defined lung tumour antigens has been investigated in in vitro-derived multidrug-resistant (MDR) variants of small cell (SCLC) and non-small cell (NSCLC) lung tumour cell lines. The majority of Moabs tested reacted equally well with MDR and drug-sensitive SCLC and NSCLC cells. However, in contrast to drug sensitive SCLC cells, MDR-SCLC cells failed to express the glycolipid antigen defined by Moab LCA1/LC38, showed increased expression of 2 glycoproteins, defined by Moabs LAM8 and SWA 4, and increased expression of the sugar epitope defined by Moab MOv15. Drug resistant large cell lung cancer cells also showed increased expression of the glycoprotein defined by Moab SWA 4 compared to the parent line which failed to react with this Moab. No significant differences were observed in the expression of lung tumour antigens by drug sensitive and resistant adenocarcinoma cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
